DK2344471T3 - 7-piperidinalkyl-3,4-dihydroquinolon-derivat - Google Patents

7-piperidinalkyl-3,4-dihydroquinolon-derivat

Info

Publication number: DK2344471T3
Authority: DK; Denmark
Prior art keywords: piperidinealkyl; dihydroquinolone; derivative; dihydroquinolone derivative
Prior art date: 2008-10-02

Application number

DK09817928.6T

Other languages

English (en)

Inventor

Kosuke Kanuma

Naoki Miyakoshi

Madoka Kawamura

Tsuyoshi Shibata

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-02

Filing date

2009-09-30

Publication date

2013-10-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2344471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-30 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2013-10-07 Application granted granted Critical

2013-10-07 Publication of DK2344471T3 publication Critical patent/DK2344471T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK09817928.6T 2008-10-02 2009-09-30 7-piperidinalkyl-3,4-dihydroquinolon-derivat DK2344471T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008257072		2008-10-02
PCT/JP2009/067441 WO2010038901A1 (en)	2008-10-02	2009-09-30	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (1)

Publication Number	Publication Date
DK2344471T3 true DK2344471T3 (da)	2013-10-07

Family

ID=42073652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09817928.6T DK2344471T3 (da)	2008-10-02	2009-09-30	7-piperidinalkyl-3,4-dihydroquinolon-derivat

Country Status (28)

Country	Link
US (1)	US8461182B2 (da)
EP (1)	EP2344471B1 (da)
JP (1)	JP5541279B2 (da)
KR (1)	KR20110067026A (da)
CN (1)	CN102239159B (da)
AR (1)	AR073727A1 (da)
AU (1)	AU2009300607C1 (da)
BR (1)	BRPI0925343A2 (da)
CA (1)	CA2739513A1 (da)
CL (1)	CL2011000734A1 (da)
CO (1)	CO6321164A2 (da)
CY (1)	CY1114165T1 (da)
DK (1)	DK2344471T3 (da)
ES (1)	ES2424393T3 (da)
HR (1)	HRP20130728T1 (da)
IL (1)	IL212070A (da)
MX (1)	MX2011003500A (da)
MY (1)	MY154337A (da)
NZ (1)	NZ592008A (da)
PE (1)	PE20110410A1 (da)
PL (1)	PL2344471T3 (da)
PT (1)	PT2344471E (da)
RS (1)	RS52964B (da)
RU (1)	RU2498981C2 (da)
SI (1)	SI2344471T1 (da)
UA (1)	UA105187C2 (da)
WO (1)	WO2010038901A1 (da)
ZA (1)	ZA201102315B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011219467A (ja) *	2010-03-26	2011-11-04	Taisho Pharmaceutical Co Ltd	７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
CA2816753A1 (en)	2010-11-08	2012-05-18	Lycera Corporation	N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
JP6242868B2 (ja)	2012-05-08	2017-12-06	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
AU2013259737A1 (en)	2012-05-08	2014-10-02	Lycera Corporation	Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
CN109939092B (zh)	2013-03-12	2022-03-22	比皮艾思药物研发有限公司	用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
WO2015095795A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en)	2013-12-20	2017-10-10	Lycera Corporation	Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9663502B2 (en)	2013-12-20	2017-05-30	Lycera Corporation	2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
JP2017507950A (ja)	2014-02-27	2017-03-23	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
US9896441B2 (en)	2014-05-05	2018-02-20	Lycera Corporation	Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja)	2014-05-05	2019-05-29	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
EP3256450B1 (en)	2015-02-11	2020-12-02	Merck Sharp & Dohme Corp.	Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
JP2018515491A (ja)	2015-05-05	2018-06-14	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
KR20180025894A (ko)	2015-06-11	2018-03-09	라이세라 코퍼레이션	Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
AU2016344118A1 (en)	2015-10-27	2018-05-10	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017075178A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
RU2018117503A (ru)	2015-10-27	2019-11-28	Мерк Шарп И Доум Корп.	ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
BR112018016475A2 (en) *	2016-02-12	2018-12-26	Cytokinetics, Incorporated	tetrahydroisoquinoline derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI0850235T1 (en) *	1995-09-15	2000-04-30	Sanofi-Synthelabo	Quinolein-2(1h)-one derivatives as serotonin antagonists
JP2005523237A (ja)	2001-10-01	2005-08-04	大正製薬株式会社	Ｍｃｈ受容体アンタゴニスト
US7183415B2 (en) *	2001-10-25	2007-02-27	Takeda Pharmaceutical Company Limited	Quinoline compound
US20050197350A1 (en)	2003-03-31	2005-09-08	Taisho Pharmaceutical Co., Ltd.	Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
JP2006522109A (ja)	2003-03-31	2006-09-28	大正製薬株式会社	新規なキナゾリン誘導体及びそれらの使用に関連する治療方法
US20050209274A1 (en) *	2004-02-26	2005-09-22	Lynch John K	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US20090036448A1 (en)	2004-03-30	2009-02-05	Taisho Pharmecutical Co., Ltd.	Pyrimidine derivatives and methods of treatment related to the use thereof
US20080090863A1 (en)	2004-09-30	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
WO2008044632A1 (en) *	2006-10-06	2008-04-17	Taisho Pharmaceutical Co., Ltd.	1-naphthyl alkylpiperidine derivative

2009
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Ceased
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en not_active Ceased
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 RS RS20130370A patent/RS52964B/sr unknown
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 HR HRP20130728AT patent/HRP20130728T1/hr unknown
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown

Also Published As

Publication number	Publication date
RU2498981C2 (ru)	2013-11-20
JP2012504549A (ja)	2012-02-23
CO6321164A2 (es)	2011-09-20
KR20110067026A (ko)	2011-06-20
CN102239159A (zh)	2011-11-09
RU2011117161A (ru)	2012-11-10
ES2424393T3 (es)	2013-10-01
HRP20130728T1 (en)	2013-10-11
AU2009300607B2 (en)	2014-02-27
IL212070A (en)	2014-07-31
AU2009300607C1 (en)	2014-08-07
US20110178304A1 (en)	2011-07-21
US8461182B2 (en)	2013-06-11
MX2011003500A (es)	2011-05-02
HK1159622A1 (en)	2012-08-03
IL212070A0 (en)	2011-06-30
CA2739513A1 (en)	2010-04-08
AU2009300607A1 (en)	2010-04-08
NZ592008A (en)	2011-12-22
CL2011000734A1 (es)	2011-09-23
EP2344471B1 (en)	2013-07-24
PL2344471T3 (pl)	2013-12-31
EP2344471A4 (en)	2012-05-30
JP5541279B2 (ja)	2014-07-09
ZA201102315B (en)	2012-06-27
WO2010038901A1 (en)	2010-04-08
SI2344471T1 (sl)	2013-11-29
PT2344471E (pt)	2013-08-01
AR073727A1 (es)	2010-11-24
PE20110410A1 (es)	2011-07-02
RS52964B (sr)	2014-02-28
CN102239159B (zh)	2014-06-25
MY154337A (en)	2015-05-29
UA105187C2 (uk)	2014-04-25
BRPI0925343A2 (pt)	2015-07-28
CY1114165T1 (el)	2016-08-31
EP2344471A1 (en)	2011-07-20

Publication	Publication Date	Title
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
DK2344471T3 (da)	2013-10-07	7-piperidinalkyl-3,4-dihydroquinolon-derivat
HRP20151058T1 (xx)	2015-12-04	Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
EP2376493A4 (en)	2012-05-30	DIHYDROPYRIMIDOPYRIMIDINDERIVAT
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
EP2380877A4 (en)	2012-06-27	PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
EP2336132A4 (en)	2012-03-21	MORPHOLINPURINDERIVAT
DK2342454T3 (da)	2013-10-28	Vindkraftanlæg
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
EP2308156A4 (en)	2014-02-19	STEP ACTUATOR
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
EP2257170A4 (en)	2011-08-03	TETRAHYDROFUROPYRIDONE
ATE545635T1 (de)	2012-03-15	Substituierte n-oxidpyrazinderivate
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
DK2442870T3 (da)	2014-06-30	Pyrazinooxazepin-derivater.
ATE534634T1 (de)	2011-12-15	2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0912716A2 (pt)	2015-10-13	composto.
FI20085425A0 (fi)	2008-05-08	Sulfaattiesihydrolyysikeittomenetelmä
EP2384285A4 (en)	2012-09-05	SHEAR CUTTING DECOUPLING LAYER